Hansa Biopharma AB (HNSA)

Sell: 28.94 SEK|Buy: 29.10 SEK|Change: 0.12 (-0.41%)

Open

29.10 SEK

Previous close

29.16 SEK

Trade high

29.28 SEK

Volume

252,301

Year high

42.98 SEK

Year low

21.78 SEK

Dividend yield

–

Market capitalisation

2.90 bn SEK

P/E ratio

–

ISIN

SE0002148817

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 17/04/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Hansa Biopharma AB	- 0.41
More...

Company profile

Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary,first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.